|
Feb 20, 2026 |
Porter-Brown Benjamin
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 30, 2025 |
Jan 2, 2026 |
Butler Erin
|
Principal Accounting Officer |
Neutral |
90.0
|
+22,500
|
737.46%
|
✗
|
- |
| Dec 24, 2025 |
Dec 29, 2025 |
SLATTERY JOSEPH P
|
Director |
Buy |
95.0
|
+16,000
|
100.00%
|
✗
|
$95.8K |
| Dec 18, 2025 |
Dec 22, 2025 |
Wang Jonathan Jian
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 18, 2025 |
Dec 22, 2025 |
Wang Stephen Hui
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 18, 2025 |
Dec 22, 2025 |
SLATTERY JOSEPH P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Nov 7, 2025 |
SLATTERY JOSEPH P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jul 25, 2025 |
Oct 10, 2025 |
Wang Stephen Hui
|
Director |
Neutral |
90.0
|
+250,721
|
100.00%
|
✗
|
- |
|
Oct 10, 2025 |
Wang Stephen Hui
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jul 25, 2025 |
Aug 15, 2025 |
Wang Jonathan Jian
|
Director |
Neutral |
90.0
|
+1,115,005
|
100.00%
|
✗
|
- |
|
Aug 15, 2025 |
Wang Jonathan Jian
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jul 25, 2025 |
Aug 7, 2025 |
Lu Yufang
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Aug 7, 2025 |
Lu Yufang
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jul 28, 2025 |
Jul 30, 2025 |
Yarema Kristin
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jul 25, 2025 |
Jul 30, 2025 |
ORBIMED ADVISORS LLC
|
Director |
Neutral |
90.0
|
+83,611
|
12.25%
|
✗
|
- |
| Jul 25, 2025 |
Jul 30, 2025 |
Bonita David P
|
Director |
Buy |
100.0
|
+83,611
|
12.25%
|
✗
|
$2.5M |
| Jul 25, 2025 |
Jul 30, 2025 |
Stampacchia Otello
|
Director |
Buy |
100.0
|
+267,556
|
142.75%
|
✗
|
$8M |
| Jul 28, 2025 |
Jul 29, 2025 |
Marango Jotin
|
CFO |
Sell |
95.0
|
+11,146
|
100.00%
|
✗
|
$79.5K |
| Jul 25, 2025 |
Jul 29, 2025 |
Butler Erin
|
Principal Accounting Officer |
Neutral |
90.0
|
+3,051
|
100.00%
|
✗
|
- |
|
Jul 29, 2025 |
Butler Erin
|
Principal Accounting Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Jul 29, 2025 |
Yarema Kristin
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 7, 2024 |
Jun 10, 2024 |
FORMELA JEAN FRANCOIS
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 7, 2024 |
Jun 10, 2024 |
Wooster Richard
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 7, 2024 |
Jun 10, 2024 |
Bonita David P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 7, 2024 |
Jun 10, 2024 |
Dukes Iain D.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 7, 2024 |
Jun 10, 2024 |
Hughes Owen
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 7, 2024 |
Jun 10, 2024 |
Koehler Maria
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 7, 2024 |
Jun 10, 2024 |
Stampacchia Otello
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Mar 1, 2024 |
Mar 5, 2024 |
Germa Caroline
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Mar 5, 2024 |
Germa Caroline
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 1, 2024 |
Feb 2, 2024 |
Ecsedy Jeffrey
|
Chief Development Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 1, 2024 |
Feb 2, 2024 |
Marango Jotin
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 1, 2024 |
Feb 2, 2024 |
Manfredi Mark
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Aug 4, 2023 |
Sep 21, 2023 |
Bonita David P
|
Director |
Neutral |
77.5
|
+153,121
|
2.01%
|
✗
|
- |
| Aug 4, 2023 |
Sep 21, 2023 |
ORBIMED ADVISORS LLC
|
Director |
Neutral |
77.5
|
+153,121
|
2.01%
|
✗
|
- |
| Aug 4, 2023 |
Sep 14, 2023 |
ORBIMED ADVISORS LLC
|
Director |
Neutral |
77.5
|
+153,121
|
1.99%
|
✗
|
- |
| Aug 4, 2023 |
Sep 14, 2023 |
Bonita David P
|
Director |
Neutral |
77.5
|
+153,121
|
1.99%
|
✗
|
- |
| Jun 9, 2023 |
Jun 13, 2023 |
Dukes Iain D.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2023 |
Jun 13, 2023 |
Hughes Owen
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2023 |
Jun 13, 2023 |
Stampacchia Otello
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2023 |
Jun 13, 2023 |
Bonita David P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2023 |
Jun 13, 2023 |
Koehler Maria
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2023 |
Jun 13, 2023 |
Wooster Richard
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2023 |
Jun 13, 2023 |
FORMELA JEAN FRANCOIS
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 5, 2023 |
Santillana Sergio L.
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 5, 2023 |
Ecsedy Jeffrey
|
Chief Development Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 5, 2023 |
Zhang Xiaoyan Michelle
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 5, 2023 |
Manfredi Mark
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 5, 2023 |
Marango Jotin
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 15, 2022 |
Dec 19, 2022 |
Hughes Owen
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 19, 2022 |
Hughes Owen
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 22, 2022 |
Jun 24, 2022 |
ORBIMED ADVISORS LLC
|
Director |
Sell |
17.5
|
-252,225
|
-1.83%
|
✗
|
$1.1M |
| Jun 22, 2022 |
Jun 24, 2022 |
Bonita David P
|
Director |
Sell |
17.5
|
-252,225
|
-1.83%
|
✗
|
$1.1M |
| Jun 9, 2022 |
Jun 13, 2022 |
Stampacchia Otello
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2022 |
Jun 13, 2022 |
Dukes Iain D.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2022 |
Jun 13, 2022 |
Renaud Ronald C JR
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2022 |
Jun 13, 2022 |
FORMELA JEAN FRANCOIS
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2022 |
Jun 13, 2022 |
Bonita David P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2022 |
Jun 13, 2022 |
Wooster Richard
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 9, 2022 |
Jun 13, 2022 |
Koehler Maria
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Apr 25, 2022 |
Apr 25, 2022 |
Marango Jotin
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Apr 25, 2022 |
Marango Jotin
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Feb 24, 2022 |
Oliveira Francisco
|
Principal Accounting Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 2, 2022 |
Feb 4, 2022 |
Zhang Xiaoyan Michelle
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 2, 2022 |
Feb 4, 2022 |
Santillana Sergio L.
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 3, 2022 |
Feb 4, 2022 |
Manfredi Mark
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 2, 2022 |
Feb 4, 2022 |
Ecsedy Jeffrey
|
Chief Development Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 2, 2022 |
Feb 4, 2022 |
Tessier Maude
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 21, 2022 |
Jan 25, 2022 |
Wooster Richard
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Jan 25, 2022 |
Wooster Richard
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 18, 2022 |
Jan 20, 2022 |
Tessier Maude
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 10, 2022 |
Jan 12, 2022 |
Zhang Xiaoyan Michelle
|
Chief Scientific Officer |
Sell |
48.8
|
-1,000
|
-1.11%
|
✓
|
$12K |
| Dec 21, 2021 |
Dec 23, 2021 |
Koehler Maria
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 21, 2021 |
Dec 23, 2021 |
Stampacchia Otello
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 21, 2021 |
Dec 23, 2021 |
FORMELA JEAN FRANCOIS
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 21, 2021 |
Dec 23, 2021 |
Dukes Iain D.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 21, 2021 |
Dec 23, 2021 |
Renaud Ronald C JR
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 21, 2021 |
Dec 23, 2021 |
Bonita David P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 10, 2021 |
Dec 14, 2021 |
Zhang Xiaoyan Michelle
|
Chief Scientific Officer |
Sell |
26.3
|
-1,000
|
-2.20%
|
✗
|
$14.8K |
| Mar 30, 2021 |
Dec 14, 2021 |
FORMELA JEAN FRANCOIS
|
Director |
Buy |
87.5
|
+98,722
|
2.18%
|
✗
|
$1.6M |
| Mar 30, 2021 |
Dec 14, 2021 |
Atlas Venture Fund XI, L.P.
|
10% Owner |
Buy |
92.5
|
+98,722
|
4.89%
|
✗
|
$1.6M |
| Nov 22, 2021 |
Nov 23, 2021 |
Zhang Xiaoyan Michelle
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Nov 23, 2021 |
Zhang Xiaoyan Michelle
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Apr 15, 2021 |
May 3, 2021 |
Koehler Maria
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Apr 15, 2021 |
Apr 15, 2021 |
Koehler Maria
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Apr 15, 2021 |
Koehler Maria
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Mar 30, 2021 |
Apr 14, 2021 |
Bonita David P
|
Director |
Buy |
100.0
|
+423,400
|
27.98%
|
✗
|
$6.8M |
| Mar 30, 2021 |
Apr 13, 2021 |
ORBIMED ADVISORS LLC
|
Director |
Buy |
100.0
|
+423,400
|
27.98%
|
✗
|
$6.8M |
| Mar 30, 2021 |
Apr 1, 2021 |
FORMELA JEAN FRANCOIS
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Mar 30, 2021 |
Apr 1, 2021 |
Stampacchia Otello
|
Director |
Neutral |
90.0
|
+450,000
|
25.01%
|
✗
|
- |
| Mar 30, 2021 |
Apr 1, 2021 |
Atlas Venture Fund X, L.P.
|
10% Owner |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Mar 30, 2021 |
Apr 1, 2021 |
Bonita David P
|
Director |
Buy |
100.0
|
+423,400
|
22.46%
|
✗
|
$6.8M |
| Mar 30, 2021 |
Apr 1, 2021 |
ORBIMED ADVISORS LLC
|
Director |
Buy |
100.0
|
+423,400
|
22.46%
|
✗
|
$6.8M |
|
Mar 30, 2021 |
Santillana Sergio L.
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Mar 25, 2021 |
Stampacchia Otello
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Mar 25, 2021 |
Tessier Maude
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Mar 25, 2021 |
Santillana Sergio L.
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Mar 25, 2021 |
Ecsedy Jeffrey
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Mar 25, 2021 |
Renaud Ronald C JR
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Mar 25, 2021 |
ORBIMED ADVISORS LLC
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |